Ownership Capital B.V. Sells 200,754 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ownership Capital B.V. lowered its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 6.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,792,265 shares of the medical research company's stock after selling 200,754 shares during the quarter. Edwards Lifesciences accounts for about 7.6% of Ownership Capital B.V.'s investment portfolio, making the stock its 2nd largest position. Ownership Capital B.V. owned about 0.47% of Edwards Lifesciences worth $206,711,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its stake in shares of Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock valued at $2,080,845,000 after buying an additional 14,610,123 shares during the period. Jennison Associates LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at approximately $555,939,000. Assenagon Asset Management S.A. lifted its position in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company's stock worth $314,182,000 after acquiring an additional 3,506,886 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in shares of Edwards Lifesciences by 239.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company's stock worth $243,745,000 after purchasing an additional 2,606,950 shares in the last quarter. Finally, Seilern Investment Management Ltd bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $109,490,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Down 1.6 %

Shares of EW traded down $1.19 during trading hours on Friday, hitting $73.52. 1,535,085 shares of the stock traded hands, compared to its average volume of 4,375,134. The business has a fifty day moving average of $72.86 and a 200-day moving average of $69.86. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $43.36 billion, a PE ratio of 10.55, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other news, Director Steven R. Loranger sold 5,739 shares of the business's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,489 shares of company stock valued at $2,002,829. Company insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and raised their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Barclays lifted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. increased their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a "neutral" rating in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.